HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis

被引：5

作者：

Al-azawi, Dhafir ^{[1
,3
]}

Leong, Sum ^{[1
]}

Wong, Limy ^{[1
]}

Kay, Elaine ^{[2
]}

Hill, Arnold D. K. ^{[1
,3
]}

Young, Leonie ^{[3
]}

机构：

[1] Beaumont Hosp, Dept Surg, Dublin 9, Ireland

[2] Beaumont Hosp, Dept Histopathol, Dublin 9, Ireland

[3] Royal Coll Surgeons Ireland, Ctr Mol & Surg Res, Dublin 2, Ireland

来源：

CANCER INVESTIGATION | 2011年 / 29卷 / 05期

关键词：

Breast cancers; Cancer biomarkers; Chemotherapy; EXPRESSION; MUTATIONS; C-ERBB-2; PROTEIN; COEXPRESSION; SURVIVAL; OVEREXPRESSION; AMPLIFICATION; RECEPTOR; IMPACT;

D O I：

10.3109/07357907.2011.584586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

p53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02). p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.

引用

页码：365 / 369

页数：5

共 50 条

[31] p53 mutation, deprivation and poor prognosis in primary breast cancer
L Baker
P R Quinlan
N Patten
A Ashfield
L-J Birse-Stewart-Bell
C McCowan
J-C Bourdon
C A Purdie
L B Jordan
J A Dewar
L Wu
A M Thompson
[J]. British Journal of Cancer, 2010, 102 : 719 - 726
[32] Correlation of ER, PgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer
Lu, Xiaowei
Gu, Yumei
Ding, Yun
Song, Wei
Mao, Jinfeng
Tan, Jianxin
Zhao, Hua
Han, Xiao
Sun, Yujie
[J]. BREAST JOURNAL, 2008, 14 (03): : 308 - 310
[33] Overexpression of p95HER2 in breast cancer is associated with poor prognosis
Rebecca Ireland
[J]. Nature Clinical Practice Oncology, 2006, 3 (5): : 235 - 235
[34] p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer
Linn, SC
Honkoop, AH
Hoekman, K
vanderValk, P
Pinedo, HM
Giaccone, G
[J]. BRITISH JOURNAL OF CANCER, 1996, 74 (01) : 63 - 68
[35] p53 and HER-2/neu overexpression in ovarian borderline tumors
Eltabbakh, GH
Belinson, JL
Kennedy, AW
Biscotti, CV
Casey, G
Tubbs, RR
[J]. GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 218 - 224
[36] Clinicopathologic significance of Her-2 and P53 expressions in gastric cancer
Zhang, Xiaoyu
Wang, Mingchuan
Wang, Yizhuo
Cheng, Xianbin
Jiang, Yang
Xiao, Huijie
[J]. ASIAN JOURNAL OF SURGERY, 2023, 46 (01) : 526 - 531
[37] p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis
Lens, D
Dyer, MJS
Garcia-Marco, JM
De Schouwer, PJJC
Hamoudi, RA
Jones, D
Farahat, N
Matutes, E
Catovsky, D
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) : 848 - 857
[38] P53 gene mutations are associated with poor prognosis in adenocarcinoma of the lung
Jassem, E
Rosell, R
Monzo, M
De Anta, JM
Skokowski, J
Badzio, A
Roszkiewicz, A
Jassem, J
[J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S251 - S251
[39] Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Coutant, Charles
Rouzier, Roman
Qi, Yuan
Lehmann-Che, Jacqueline
Bianchini, Giampaolo
Iwamoto, Takayuki
Hortobagyi, Gabriel N.
Symmans, W. Fraser
Uzan, Serge
Andre, Fabrice
de The, Hugues
Pusztai, Lajos
[J]. CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2591 - 2601
[40] P53, Her-2/neu and VEGF determined immunohisochemically in chondrosarcoma
Kharatishvily, TK
Stepanova, E
Mousaev, ER
Aliev, MD
[J]. INTERNATIONAL JOURNAL OF CANCER, 2002, : 274 - 274

← 1 2 3 4 5 →